Cytomegalovirus secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Cytomegalovirus}} {{CMG}} ==Secondary Prevention== Recommendations for pregnant women with regard to CMV infection: *Women who develop a mononucleosis-like il...") |
No edit summary |
||
| Line 9: | Line 9: | ||
*The demonstrated benefits of breast-feeding outweigh the minimal risk of acquiring CMV from the breast-feeding mother. | *The demonstrated benefits of breast-feeding outweigh the minimal risk of acquiring CMV from the breast-feeding mother. | ||
*There is no need to either screen for CMV or exclude CMV-excreting children from schools or institutions because the virus is frequently found in many healthy children and adults. | *There is no need to either screen for CMV or exclude CMV-excreting children from schools or institutions because the virus is frequently found in many healthy children and adults. | ||
Patients without CMV [[infection]] who are given [[organ transplant]]s from CMV-infected donors should be given [[prophylactic]] treatment with [[valganciclovir]] (ideally) or [[ganciclovir]] and require regular [[serologic]]al monitoring to detect a rising CMV [[titre]], which should be treated early to prevent a potentially life-threatening infection becoming established. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:06, 14 December 2012
Template:Cytomegalovirus Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Secondary Prevention
Recommendations for pregnant women with regard to CMV infection:
- Women who develop a mononucleosis-like illness during pregnancy should be evaluated for CMV infection and counseled about the possible risks to the unborn child.
- Recovery of CMV from the cervix or urine of women at or before the time of delivery does not warrant a cesarean section.
- The demonstrated benefits of breast-feeding outweigh the minimal risk of acquiring CMV from the breast-feeding mother.
- There is no need to either screen for CMV or exclude CMV-excreting children from schools or institutions because the virus is frequently found in many healthy children and adults.
Patients without CMV infection who are given organ transplants from CMV-infected donors should be given prophylactic treatment with valganciclovir (ideally) or ganciclovir and require regular serological monitoring to detect a rising CMV titre, which should be treated early to prevent a potentially life-threatening infection becoming established.